James Goldschmidt

Dr. Goldschmidt joined CASI in April 2016 as Senior Vice President of Business Development. Currently he serves as Chief Business Development Officer.

Before joining CASI, he held senior positions at several biopharmaceutical companies such as Johnson & Johnson, Wyeth/Pfizer, and GSK. Dr. Goldschmidt brings more than 25 years of commercial and business development experience in the biotechnology and pharmaceutical sectors and had direct leadership responsibilities for the development, launch and brand marketing of numerous products including Velcade^®, Yondelis^®, Mylotarg^®, Torisel^®, Hycamtin^®, and Doxil^®.

Dr. Goldschmidt is a graduate of Villanova University and went on to receive a master’s degree from Drexel University and Ph.D. from Temple University School of Medicine.